Clinical trials: Liver Inflammation
Chronic Hepatitis C
Virological Response Study of the HCV Vaccine IC41
The objective is to investigate the virological (HCV-RNA) responses following biweekly immunization with IC41. Treatment phase 14 weeks, total study duration including follow-up period 38 weeks.
- Trial name
- NCT00601770
- Testing
- IC41
- Where
- 8 sites in Germany, Poland and 1 more
- Volunteers
- 71 people
- Sponsor
- Valneva Austria GmbH
Chronic Hepatitis C Genotype-1 Relapse
Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients
This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone.
- Trial name
- NCT00983060
- Testing
- NIM811
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Chronic
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B
This multicenter, prospective, observational study will evaluate the efficacy and safety of Pegasys (peginterferon alfa-2a) in routine clinical practice in patients with HBeAg-positive or HBeAg-negative chronic hepatitis B.
- Trial name
- NCT01734018
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis B
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus…
- Trial name
- NCT04398134
- Testing
- ABI-H2158, Entecavir (ETV)
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 88 people
- Sponsor
- Assembly Biosciences
Hepatitis B
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.
- Trial name
- NCT00128544
- Testing
- telbivudine, valtorcitabine
- Where
- 3 sites in Hong Kong, New Zealand and 1 more
- Volunteers
- 130 people
- Sponsor
- Novartis
Chronic Hepatitis C
The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects
A Phase Ib/IIa, Single Center, Randomized, open, Sofosbuvir-controlled, Multiple Ascending Dose Study to Access the Tolerability，Pharmacokinetics and Pharmacodynamics of HEC110114 Tablets in HCV-infected Subjects
- Trial name
- HEC110114 (NCT04202952)
- Testing
- HEC110114 Tablet, Sofosbuvir Tablet
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Chronic Hepatitis C Infection
Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients
The primary objective of this protocol is to study the effect of the standard of care in hepatitis C (pegylated interferon and ribavirin) associated with therapeutic vaccine TG4040 on the viral load of treatment-naïve patients…
- Trial name
- HCVac (NCT01055821)
- Testing
- pegylated interferon and ribavirin, TG4040 + SOC
- Where
- Germany
- Volunteers
- 140 people
- Sponsor
- Transgene
Diphtheria, Hepatitis B
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infants
In this study, infants will be randomly allocated into three groups: one group of subjects will receive DTPa-HBV-IPV/Hib vaccine (new formulation) the second group of subjects will receive DTPa-HBV-IPV/Hib vaccine (current…
- Conditions
- Diphtheria, Hepatitis B, Poliomyelitis, Tetanus
- Trial name
- NCT00320463
- Testing
- DTPa-HBV-IPV/Hib vaccine
- Where
- 4 sites in Russia
- Volunteers
- 415 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B
This is an open-label study evaluating multiple doses of GS-7340 versus Tenofovir disoproxil fumarate (TDF).
- Trial name
- NCT01671787
- Testing
- GS-7340, Tenofovir disoproxil fumarate
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 51 people
- Sponsor
- Gilead Sciences
Hepatitis C
Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment
The main objective of this study is to investigate the influence of mild, moderate and severe renal impairment on the pharmacokinetics and safety of BI 201335 in comparison to a control group with normal renal function after…
- Trial name
- NCT01580306
- Testing
- BI 201335
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis b
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection
This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.
- Trial name
- NCT04980482
- Testing
- AB-729, Peg-IFNα-2a
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 43 people
- Sponsor
- Arbutus Biopharma Corporation
Hepatitis B, Chronic
A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B
This study is a long-term post-treatment follow-up to study WV19432, which evaluated the efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B (CHB).Patients who received treatment with PEGASYS, and…
- Trial name
- NCT00927082
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 31 sites in Australia, Brazil and 8 more
- Volunteers
- 383 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic, Hepatitis C
Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690)
Participants will receive PegIntron injection pen (Peginterferon alfa-2b) and Rebetol (Ribavirin) combination therapy as their usual medical treatment.
- Trial name
- NCT00725205
- Testing
- PegIntron (Peginterferon alfa-2b), Rebetol (Ribavirin)
- Volunteers
- 294 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis D Infection With Hepatitis B
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
This is a multicenter, open-label, randomized clinical trial to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination with Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients…
- Trial name
- NCT03546621
- Testing
- Myrcludex B, Myrcludex-B, Tenofovir
- Where
- 15 sites in Germany, Russia
- Volunteers
- 120 people
- Sponsor
- Hepatera Ltd.
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
This study is to evaluate lot-lot consistency of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin®.
- Trial name
- NCT03365921
- Testing
- Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Hepatitis C
Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C Infection
The purpose of this study is to assess antiviral activity when administered alone for 3 days or in combination with peginterferon and ribavirin for 12 weeks.
- Trial name
- NCT00911963
- Testing
- peginterferon alfa-2a, ribavirin
- Where
- 10 sites in United States, Argentina and 2 more
- Volunteers
- 49 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Hepatitis B, Diphtheria
Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.
The purpose of this study is to compare the reactogenicity \& safety of Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care, Tritanrix™-HepB/Hiberix™.
- Conditions
- Hepatitis B, Diphtheria, Whole Cell Pertussis, Tetanus
- Trial name
- NCT00317187
- Testing
- Tritanrix-HepB/Meningitec conjugate vaccine, Tritanrix/Hiberix vaccine
- Where
- Thailand
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.
This study will evaluate the efficacy and safety of PEGASYS (peginterferon alfa-2a) in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT01519921
- Testing
- peginterferon alfa-2a [Pegasys]
- Where
- 7 sites in South Korea
- Volunteers
- 150 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C
A Study Investigating the Influence of Hepatic Insufficiency on the Pharmacokinetics of Vaniprevir (MK-7009-005)
This was a 3-part study comparing the pharmacokinetics after administration of vaniprevir (MK-7009) for participants with mild, moderate or severe hepatic insufficiency with healthy matched control participants.
- Trial name
- NCT01010906
- Testing
- Vaniprevir 300 mg, Vaniprevir 200 mg
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in chronic hepatitis C patients
- Trial name
- VGX-6150-01 (NCT02027116)
- Testing
- VGX-6150
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- GeneOne Life Science, Inc.